Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cryo Cell International (CCEL) Operating Leases (2020 - 2025)

Cryo Cell International (CCEL) has disclosed Operating Leases for 5 consecutive years, with $505053.0 as the latest value for Q4 2024.

  • On a quarterly basis, Operating Leases fell 40.72% to $505053.0 in Q4 2024 year-over-year; TTM through Nov 2024 was $505053.0, a 40.72% decrease, with the full-year FY2024 number at $505053.0, down 40.72% from a year prior.
  • Operating Leases was $505053.0 for Q4 2024 at Cryo Cell International, down from $851938.0 in the prior quarter.
  • In the past five years, Operating Leases ranged from a high of $910123.0 in Q3 2023 to a low of $242039.0 in Q4 2021.
  • A 5-year average of $508709.3 and a median of $496475.0 in 2020 define the central range for Operating Leases.
  • Peak YoY movement for Operating Leases: soared 171.93% in 2023, then plummeted 40.72% in 2024.
  • Cryo Cell International's Operating Leases stood at $496475.0 in 2020, then plummeted by 51.25% to $242039.0 in 2021, then grew by 29.44% to $313298.0 in 2022, then skyrocketed by 171.93% to $851938.0 in 2023, then tumbled by 40.72% to $505053.0 in 2024.
  • Per Business Quant, the three most recent readings for CCEL's Operating Leases are $505053.0 (Q4 2024), $851938.0 (Q4 2023), and $910123.0 (Q3 2023).